DOI QR코드

DOI QR Code

Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation

  • Lee, Seung-Shin (Department of Hematology and Oncology, Chonnam National University Hwasun Hospital) ;
  • Ahn, Jae-Sook (Department of Hematology and Oncology, Chonnam National University Hwasun Hospital) ;
  • Jung, Sung-Hoon (Department of Hematology and Oncology, Chonnam National University Hwasun Hospital) ;
  • Ahn, Seo-Yeon (Department of Hematology and Oncology, Chonnam National University Hwasun Hospital) ;
  • Kim, Jae-Yong (Department of Hematology and Oncology, Chonnam National University Hwasun Hospital) ;
  • Jang, Hee-Chang (Department of Infectious Disease, Chonnam National University Hwasun Hospital) ;
  • Kang, Seung-Ji (Department of Infectious Disease, Chonnam National University Hwasun Hospital) ;
  • Jang, Mi-Ok (Department of Infectious Disease, Chonnam National University Hwasun Hospital) ;
  • Yang, Deok-Hwan (Department of Hematology and Oncology, Chonnam National University Hwasun Hospital) ;
  • Kim, Yeo-Kyeoung (Department of Hematology and Oncology, Chonnam National University Hwasun Hospital) ;
  • Lee, Je-Jung (Department of Hematology and Oncology, Chonnam National University Hwasun Hospital) ;
  • Kim, Hyeoung-Joon (Department of Hematology and Oncology, Chonnam National University Hwasun Hospital)
  • 투고 : 2014.03.18
  • 심사 : 2014.07.07
  • 발행 : 2015.03.01

초록

Background/Aims: BK virus (BKV) has been associated with late-onset hemorrhagic cystitis (HC) in recipients of hematopoietic stem cell transplantation (HSCT). Cidofovir has been used at higher doses (3 to 5 mg/kg/wk) with probenecid prophylaxis; however, cidofovir may result in nephrotoxicity or cytopenia at high doses. Methods: Allogeneic HSCT recipients with BKV-associated HC are treated with 1 mg/kg intravenous cidofovir weekly at our institution. A microbiological response was defined as at least a one log reduction in urinary BKV viral load, and a clinical response was defined as improvement in symptoms and stability or reduction in cystitis grade. Results: Eight patients received a median of 4 weekly (range, 2 to 11) doses of cidofovir. HC occurred a median 69 days (range, 16 to 311) after allogeneic HSCT. A clinical response was detected in 7/8 patients (86%), and 4/5 (80%) had a measurable microbiological response. One patient died of uncontrolled graft-versus-host disease; therefore, we could not measure the clinical response to HC treatment. One microbiological non-responder had a stable BKV viral load with clinical improvement. Only three patients showed transient grade 2 serum creatinine toxicities, which resolved after completion of concomitant calcineurin inhibitor treatment. Conclusions: Weekly intravenous low-dose cidofovir without probenecid appears to be a safe and effective treatment option for patients with BKV-associated HC.

키워드

참고문헌

  1. Bedi A, Miller CB, Hanson JL, et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 1995;13:1103-1109. https://doi.org/10.1200/JCO.1995.13.5.1103
  2. Gorczynska E, Turkiewicz D, Rybka K, et al. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005;11:797-804. https://doi.org/10.1016/j.bbmt.2005.06.007
  3. Sencer SF, Haake RJ, Weisdorf DJ. Hemorrhagic cystitis after bone marrow transplantation: risk factors and complications. Transplantation 1993;56:875-879. https://doi.org/10.1097/00007890-199310000-00020
  4. Silva Lde P, Patah PA, Saliba RM, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica 2010;95:1183-1190. https://doi.org/10.3324/haematol.2009.016758
  5. Cesaro S, Hirsch HH, Faraci M, et al. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis 2009;49:233-240. https://doi.org/10.1086/599829
  6. Azzi A, Cesaro S, Laszlo D, et al. Human polyomavirus BK (BKV) load and haemorrhagic cystitis in bone marrow transplantation patients. J Clin Virol 1999;14:79-86. https://doi.org/10.1016/S1386-6532(99)00055-4
  7. Cesaro S, Brugiolo A, Faraci M, et al. Incidence and treatment of hemorrhagic cystitis in children given hematopoietic stem cell transplantation: a survey from the Italian association of pediatric hematology oncology-bone marrow transplantation group. Bone Marrow Transplant 2003;32:925-931. https://doi.org/10.1038/sj.bmt.1704252
  8. Miodosky M, Abdul-Hai A, Tsirigotis P, et al. Treatment of post-hematopoietic stem cell transplantation hemorrhagic cystitis with intravesicular sodium hyaluronate. Bone Marrow Transplant 2006;38:507-511. https://doi.org/10.1038/sj.bmt.1705474
  9. Savona MR, Newton D, Frame D, Levine JE, Mineishi S, Kaul DR. Low-dose cidofovir treatment of BK virusassociated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant 2007;39:783-787. https://doi.org/10.1038/sj.bmt.1705678
  10. Mackey MC. Intravesicular cidofovir for the treatment of polyomavirus-associated hemorrhagic cystitis. Ann Pharmacother 2012;46:442-446. https://doi.org/10.1345/aph.1Q430
  11. Gonzalez-Fraile MI, Canizo C, Caballero D, et al. Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis. Transpl Infect Dis 2001;3:44-46.
  12. Gaziev J, Paba P, Miano R, et al. Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir. Biol Blood Marrow Transplant 2010;16:662-671. https://doi.org/10.1016/j.bbmt.2009.12.009
  13. Brugieres L, Hartmann O, Travagli JP, et al. Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: incidence, clinical course, and outcome. J Clin Oncol 1989;7:194-199. https://doi.org/10.1200/JCO.1989.7.2.194
  14. De Clercq E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1997;10:674-693.
  15. Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997;41:587-593.
  16. Leung AY, Chan MT, Yuen KY, et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2005;40:528-537. https://doi.org/10.1086/427291
  17. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956. https://doi.org/10.1016/j.bbmt.2005.09.004
  18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-828.
  19. Hirsch HH. BK virus: opportunity makes a pathogen. Clin Infect Dis 2005;41:354-360. https://doi.org/10.1086/431488
  20. Siguier M, Sellier P, Bergmann JF. BK-virus infections: a literature review. Med Mal Infect 2012;42:181-187. https://doi.org/10.1016/j.medmal.2012.04.011
  21. Ahsan N. Polyomaviruses and Human Diseases. New York: Springer Science+Business Media, 2006.
  22. Gilis L, Morisset S, Billaud G, et al. High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2014;49:664-670. https://doi.org/10.1038/bmt.2013.235
  23. Kloos RQ, Boelens JJ, de Jong TP, Versluys B, Bierings M. Hemorrhagic cystitis in a cohort of pediatric transplantations: incidence, treatment, outcome, and risk factors. Biol Blood Marrow Transplant 2013;19:1263-1266. https://doi.org/10.1016/j.bbmt.2013.05.014
  24. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003;325:349-362. https://doi.org/10.1097/00000441-200306000-00006
  25. Appelbaum FR, Thomas ED; Wiley InterScience (Online service), et al. Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation. 4th ed. Oxford: Wiley-Blackwell, 2009.
  26. Ganguly N, Clough LA, Dubois LK, et al. Low-dose cidofovir in the treatment of symptomatic BK virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis of an algorithmic approach. Transpl Infect Dis 2010;12:406-411. https://doi.org/10.1111/j.1399-3062.2010.00513.x
  27. Kwon HJ, Kang JH, Lee JW, Chung NG, Kim HK, Cho B. Treatment of BK virus-associated hemorrhagic cystitis in pediatric hematopoietic stem cell transplant recipients with cidofovir: a single-center experience. Transpl Infect Dis 2013;15:569-574. https://doi.org/10.1111/tid.12136

피인용 문헌

  1. Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea vol.33, pp.2, 2015, https://doi.org/10.3904/kjim.2018.036
  2. Severe hemorrhagic cystitis caused by the BK polyomavirus is associated with decreased survival post‐allogeneic hematopoietic stem cell transplantation vol.21, pp.5, 2015, https://doi.org/10.1111/tid.13101
  3. Effects and long‐term follow‐up of using umbilical cord blood–derived mesenchymal stromal cells in pediatric patients with severe BK virus‐associated late‐onset hemorrhag vol.24, pp.2, 2020, https://doi.org/10.1111/petr.13618
  4. Imaging of acute abdomen in cancer patients vol.45, pp.8, 2015, https://doi.org/10.1007/s00261-019-02332-5
  5. Review of Intravesicular Cidofovir for BK Virus Hemorrhagic Cystitis vol.13, pp.3, 2015, https://doi.org/10.1007/s40506-021-00251-y
  6. Antivirals against human polyomaviruses: Leaving no stone unturned vol.31, pp.6, 2015, https://doi.org/10.1002/rmv.2220
  7. Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study vol.76, pp.11, 2021, https://doi.org/10.1093/jac/dkab259